Abstract
A PROSPECTIVE STUDY ON EVALUATION OF EFFICACY AND SAFETY OF VILAZODONE IN DEPRESSION

Jisha Vijayan*, Jereena E., Anil Babu and Anagha R.

ABSTRACT

Background and Objectives: Vilazodone a novel Serotonin Reuptake Inhibitor and 5-HT1A.Partial Agonist that is recently developed for the treatment of Major Depressive Disorder. The main objective of study to evaluate the efficacy and safety of vilazodone in depression. Methods: This is a prospective, observational, 9 month study conducted on department of psychiatry in a 500 bed tertiary care teaching hospital. The study population includes 30 subjects aged between 18-60 years with major depressive disorder (DSM-IV criteria). Vilazodone was titrated from 10 mg to 20 mg and efficacy assessed by mean change from baseline to week 4 on Hamilton Depression Rating Scale (HAMD), Montgomery-Asberg Depression Rating Scale (MADRS), Clinical Global Impression-Severity scale (CGI-S) and Improvement scale (CGI-I). Data were analysed using statistical package for social science version 20.Results and Discussion: The mean changes in HAMD-17 total scores, MADRS total score, CGI-S score and CGI-I score from baseline to week 4 were significantly greater in Vilazodone treated patients. Improvement in Hamilton Depression Rating Score, Montgomery-Asberg Depression Rating Score, Clinical Global Impression- Severity score and Improvement score were noted in 1 week, the earliest time point measured and persist till week 4 indicating reduction in depression symptomatology. Higher response and remission rate were shown by vilazodone treated patient on HAMD-17 and MADRS. Most common adverse events noted include diarrhea .Conclusion: Vilazodone is effective for treatment of Major Depressive Disorder in adults with symptom relief starting at 1 week and is well tolerated at dose of 20 mg/day.

Keywords: Vilazodone; Safety; Efficacy; Major Depressive Disorder.


[Full Text Article]   [Download Certificate]

Login





Forgot Password  |  Register

Indexing

Best Paper Awards

European Journal of Biomedical and Pharmaceutical Sciences (EJBPS) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.

Best Article of current issue :

Dr. Dhrubo Jyoti Sen

Download Article : Click here

News & Updation

  • EJBPS: MAY ISSUE PUBLISHED

    MAY 2024 Issue has been successfully launched on 1 MAY 2024.

  • EJBPS New Impact Factor

    EJBPS Impact Factor has been Increased to 7.482 for Year 2024.

  • Index Copernicus Value

    EJBPS Received Index Copernicus Value 77.3, due to High Quality Publication in EJBPS at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in EJBPS coming Issue.

     

UG/PG/Ph.D Research Publication

Research Scholar of UG/PG/Ph.D can Submit their Research Article/Review Article/Case Study/Short Communication for Publication in EJBPS

Downloads

Copyright From

Covering Letter

                        Author Instruction 
 

PLAGERLUM REPORT